Circuit Therapeutics Inc Menlo Park, CA - 94025

Circuit Therapeutics Inc is categorized under Commercial Biotechnical Research in Menlo Park, CA and active since 2010.

Circuit Therapeutics Inc was established in 2010, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.

If you are seeking more information, feel free to contact Karoly Nikolich at the company’s single location by writing to 1505 Obrien Drive, Menlo Park, California CA 94025 or by phoning (650) 324-9400. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Circuit Therapeutics Inc
Contact Person: Karoly Nikolich
Address: 1505 Obrien Drive, Menlo Park, California 94025
Phone Number: (650) 324-9400
Annual Revenue (USD): $500.000 to $999.999
Founded: 2010
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Biotechnical Research
SIC Code: 8731
NAICS Code: 541711
Share This Business:

Circuit Therapeutics Inc was started in 2010 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.

Feel free to contact Karoly Nikolich for inquiries that concern Circuit Therapeutics Inc by calling the company number (650) 324-9400, as your correspondence is most welcome. Additionally, the physical location of the single location of Circuit Therapeutics Inc can be found at the coordinates 37.476688,-122.143311 as well as the street address 1505 Obrien Drive in Menlo Park, California 94025.

For its online presence, you may visit Circuit Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.